ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

CIK: 0001845297 · Show all filings

Period: Q1 2021 (← Previous) (Next →)

Filing Date: May 17, 2021

Total Value ($000): $203,504 (100.0% shares, 0.0% debt)

Holdings (7)

— ATEA PHARMACEUTICALS INC 80.1%

Value ($000) $162,969 Shares 2,639,178 Est. Cost $61.75 Unrealized —

LUNG PULMONX CORP 18.7%

Value ($000) $38,117 Shares 833,333 Est. Cost $48.97 Unrealized +17.1%

GNCAQ GENOCEA BIOSCIENCES INC 0.5%

Value ($000) $1,016 Shares 375,000 Est. Cost $2.28 Unrealized +30.0%

— SYNLOGIC INC 0.4%

Value ($000) $737 Shares 205,906 Est. Cost $2.16 Unrealized —

— AERPIO PHARMACEUTICALS INC 0.3%

Value ($000) $516 Shares 400,000 Est. Cost $0.98 Unrealized —

— NABRIVA THERAPEUTICS PLC 0.0%

Value ($000) $76 Shares 45,849 Est. Cost $2.42 Unrealized —

— IDERA PHARMACEUTICALS INC 0.0%

Value ($000) $73 Shares 56,250 Est. Cost $3.66 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	ATEA PHARMACEUTICALS INC	2,639,178	$162,969	80.1%	$61.75	—	COM	04653R106
LUNG	PULMONX CORP	833,333	$38,117	18.7%	$48.97	+17.1%	COM	745848101
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$1,016	0.5%	$2.28	+30.0%	COM NEW	372427401
—	SYNLOGIC INC	205,906	$737	0.4%	$2.16	—	COM	87166L100
—	AERPIO PHARMACEUTICALS INC	400,000	$516	0.3%	$0.98	—	COM	00810B105
—	NABRIVA THERAPEUTICS PLC	45,849	$76	0.0%	$2.42	—	SHS	G63637113
—	IDERA PHARMACEUTICALS INC	56,250	$73	0.0%	$3.66	—	COM PAR	45168K405